Holen Sie sich die Stockscreener-App
29.53
1.57%
-0.47
Vorhandelsmarkt:
29.98
0.45
+1.52%
Schlusskurs vom Vortag:
$30.00
Offen:
$29.75
24-Stunden-Volumen:
554.71K
Relative Volume:
1.84
Marktkapitalisierung:
$488.36M
Einnahmen:
$3.25M
Nettoeinkommen (Verlust:
$-116.80M
KGV:
-9.682
EPS:
-3.05
Netto-Cashflow:
$-98.17M
1W Leistung:
+0.65%
1M Leistung:
+23.30%
6M Leistung:
+322.15%
1J Leistung:
+108.55%
1-Tages-Spanne:
$28.86
$30.00
1-Wochen-Bereich:
$25.50
$42.39
52-Wochen-Spanne:
$5.6652
$42.39
Rapt Therapeutics Inc Stock (RAPT) Company Profile
Firmenname
Rapt Therapeutics Inc
Sektor
Branche
Telefon
(650) 489-9000
Adresse
561 ECCLES AVENUE, SOUTH SAN FRANCISCO, CA
Vergleichen Sie RAPT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RAPT
Rapt Therapeutics Inc
|
29.53 | 496.13M | 3.25M | -116.80M | -98.17M | -3.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.39 | 108.36B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
463.43 | 60.82B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
577.95 | 61.02B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
817.32 | 50.01B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
310.81 | 34.05B | 4.56B | -176.77M | 225.30M | -1.7177 |
Rapt Therapeutics Inc Stock (RAPT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-20 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2025-10-13 | Eingeleitet | Barclays | Overweight |
| 2025-09-26 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-07-30 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2025-05-22 | Fortgesetzt | H.C. Wainwright | Buy |
| 2024-12-26 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2024-11-13 | Herabstufung | Stifel | Buy → Hold |
| 2024-11-11 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2024-11-11 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2024-05-14 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2024-05-10 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2024-05-10 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-02-22 | Herabstufung | UBS | Buy → Neutral |
| 2024-02-21 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2024-02-21 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-02-21 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-02-20 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2024-02-16 | Eingeleitet | Evercore ISI | Outperform |
| 2024-02-15 | Eingeleitet | Wolfe Research | Outperform |
| 2023-09-14 | Eingeleitet | Berenberg | Buy |
| 2023-08-09 | Eingeleitet | Stifel | Buy |
| 2023-06-15 | Eingeleitet | Barclays | Overweight |
| 2023-01-04 | Eingeleitet | Guggenheim | Buy |
| 2022-12-01 | Eingeleitet | Goldman | Buy |
| 2022-09-21 | Eingeleitet | CapitalOne | Overweight |
| 2022-05-24 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2021-12-09 | Eingeleitet | JP Morgan | Overweight |
| 2021-08-12 | Eingeleitet | SVB Leerink | Outperform |
| 2021-06-21 | Eingeleitet | Piper Sandler | Overweight |
| 2020-06-01 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-05-19 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-04-13 | Eingeleitet | ROTH Capital | Buy |
| 2019-11-25 | Eingeleitet | BMO Capital Markets | Outperform |
| 2019-11-25 | Eingeleitet | UBS | Buy |
| 2019-11-25 | Eingeleitet | Wells Fargo | Outperform |
Alle ansehen
Rapt Therapeutics Inc Aktie (RAPT) Neueste Nachrichten
Analyzing RAPT Therapeutics Inc. with multi timeframe chartsQuarterly Earnings Report & Verified Trade Idea Suggestions - newser.com
Why retail investors favor RAPT Therapeutics Inc. stockIPO Watch & Weekly Watchlist for Hot Stocks - newser.com
Tick level data insight on RAPT Therapeutics Inc. volatilityWeekly Earnings Recap & AI Driven Stock Price Forecasts - newser.com
Risk adjusted return profile for RAPT Therapeutics Inc. analyzedDividend Hike & AI Enhanced Trade Execution Alerts - newser.com
Published on: 2025-10-27 02:57:37 - newser.com
Can RAPT Therapeutics Inc. recover in the next quarterPortfolio Risk Summary & Comprehensive Market Scan Reports - newser.com
Is RAPT Therapeutics Inc. stock a buy for dividend growthJuly 2025 Recap & Fast Gain Swing Alerts - newser.com
What indicators show strength in RAPT Therapeutics Inc.Trade Performance Summary & Consistent Profit Focused Trading Strategies - newser.com
Published on: 2025-10-27 00:59:41 - newser.com
Does RAPT Therapeutics Inc. (0RA) stock trade below intrinsic value2025 Analyst Calls & Momentum Based Trading Signals - newser.com
Published on: 2025-10-26 23:23:14 - newser.com
Is RAPT Therapeutics Inc. stock reversal real or fakeDay Trade & Reliable Breakout Stock Forecasts - newser.com
Published on: 2025-10-26 21:27:10 - newser.com
Published on: 2025-10-26 20:42:00 - newser.com
Why RAPT Therapeutics Inc. (0RA) stock could break out in 2025Quarterly Earnings Report & Technical Entry and Exit Alerts - newser.com
Is RAPT Therapeutics Inc. (0RA) stock dividend growth reliableJuly 2025 Closing Moves & Verified Momentum Stock Ideas - newser.com
Published on: 2025-10-26 15:06:18 - newser.com
Leading vs lagging indicators on RAPT Therapeutics Inc. performanceInsider Selling & Technical Entry and Exit Tips - newser.com
Published on: 2025-10-26 10:44:52 - newser.com
Wells Fargo Boosts RAPT Therapeutics (RAPT) PT to $48 on Promising Anti-IgE Drug Data - Insider Monkey
Published on: 2025-10-26 00:53:27 - newser.com
Finanzdaten der Rapt Therapeutics Inc-Aktie (RAPT)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.11%
0.29%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):